FLT3 and acute myeloid leukemia: Pharmacological and genetic RET inhibition led to the autophagic degradation of FLT3 and depletion of FLT3-mutated AML cells, suggesting that disruption of RET signaling is a potential therapeutic strategy for FLT3-mutated AML [62].